Emcure Pharma shares list at 31% premium: Here’s how much Namita Thapar gained from share sale

2 min read | Updated on July 10, 2024, 19:36 IST

SUMMARY

The Shark Tank India fame investor has gained over 7600% with the listing of the Emcure Pharma stocks compared to her initial investment in the company. The cost of the acquisition of the Emcure Pharma stake for Namita Thapar was around ₹2.18 crore at ₹3.44 per share.

Emcure Pharma shares list at 31% premium: Here’s how much Namita Thapar gained from share sale

Emcure Pharmaceuticals made a strong debut on the stock exchanges on Wednesday, July 10, as the shares were listed at a 31% premium at ₹1,325.05 apiece on the NSE. Executive Director of Emcure Pharma and Shar Tank India investor Namita Thapar raked in around ₹168 crore with her company's remarkable debut.

Share of Emcure Pharmaceuticals opened at ₹1,325.05 apiece on the NSE, 31.45% higher than the issue price of ₹1,008 apiece. The pharma stock rallied as much as 4.52% to hit an intraday high of ₹1,385 apiece. However, the stock pared early gains amid profit booking and closed 2.95% higher at ₹1,364.2 apiece.

Namita Thapar gains ₹168 crore after premium listing of Emcure Pharma shares

Namita Thapar offloaded 12.68 lakh shares through offer-for-sale (OFS) component in the initial public offering (IPO) of the pharma company. Before Emcure Pharma's IPO launch, she owned over 63.39 lakh shares or a 3.5% stake in the company.

Through the share sale, she released 12,68,600 shares, and at the stock's listing price, she earned ₹168.01 crore (₹1,325.05x12,68,600).

Post the public issue, Namita Thapar’s shareholding in the company stands at 50,71,200 shares. At the current market price of the Emcure Pharma stocks, her stake in the company is worth nearly ₹692 crore (₹1,364.2 x 50,71,200).

The Shark Tank India fame investor has gained over 7600% with the listing of the Emcure Pharma stocks compared to her initial investment in the company. The cost of acquiring the Emcure Pharma stake for Namita Thapar was around ₹2.18 crore at ₹3.44 per share.

Emcure Pharma IPO was open for subscription from July 3 to July 5. The public issue saw a strong demand from the investors with bids for over 92.99 crore shares compared to 1.37 crore shares on offer. The issue was subscribed 67.87 times.

Emcure Pharma specialises in the development, manufacturing, and global marketing of pharmaceutical products across various therapeutic areas. The company has a presence in nearly 70 countries and operates 13 manufacturing facilities across India.

To know more about IPOs listing, schedule and upcoming IPOs, click here

About The Author

Upstox News Desk is a team of journalists who passionately cover stock markets, economy, commodities, latest business trends, and personal finance.

Upstox Securities Pvt. Ltd.: SEBI Registration No. INZ000315837 | NSE TM Code: 13942 | BSE TM Code: 6155 | CDSL Reg No.: IN-DP-761-2024 | CIN: U65100DL2021PTC376860 | Compliance Officer: Mr. Kapil Jaikalyani. Tel No.: (022) 24229920. Email ID: compliance@upstox.com | Registered Address: 809, New Delhi House, Barakhamba Road, Connaught Place, New Delhi - 110001 | RKSV Commodities India Pvt. Ltd.: SEBI Registration No.: INZ000015837 | MCX TM Code: 46510 | CIN: U74900DL2009PTC189166 | Compliance Officer: Mr. Amit Lalan. Tel No.: (022) 24229920. Email ID: compliance@rksv.in | Registered Address: 807, New Delhi House, Barakhamba Road, Connaught Place, New Delhi - 110001. Correspondence Address: 30th Floor, Sunshine Tower, Senapati Bapat Marg, Dadar (West), Mumbai - 400013. | For any complaints, email at complaints@upstox.com and complaints.mcx@upstox.com.

Procedure to file a complaint on SEBI SCORES: Register on the SCORES portal. Mandatory details for filing complaints on SCORES include: Name, PAN, Address, Mobile Number, and E-mail ID. Benefits include effective communication and speedy redressal of grievances. Please ensure you carefully read the Risk Disclosure Document as prescribed by SEBI, along with our Terms of Use and Privacy Policy.

Upstox Securities Private Limited is a wholly owned subsidiary of RKSV Securities India Private Limited and RKSV Commodities India Private Limited is an associate of RKSV Securities India Private Limited.

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing.
*Brokerage will not exceed the SEBI prescribed limit.

Risk disclosures on derivatives -

9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Mutual Funds: Top rated funds do not constitute any advice. Research data is powered by Morningstar. Please read the offer documents carefully before investing. Upstox shall not accept any liability arising out of your investments.
These are not Exchange traded products, and the Member is just acting as distributor. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism.

Attention Investors: As per NSE circular dated July 6, 2022, BSE circular dated July 6, 2022, MCX circular dated July 11, 2022 investors are cautioned to abstain them from dealing in any schemes of unauthorised collective investments/portfolio management, indicative/ guaranteed/fixed returns / payments etc. Investors are further cautioned to avoid practices like:
a) Sharing i) trading credentials – login id & passwords including OTP’s., ii) trading strategies, iii) position details.
b) Trading in leveraged products /derivatives like Options without proper understanding, which could lead to losses.
c) Writing/ selling options or trading in option strategies based on tips, without basic knowledge & understanding of the product and its risks
d) Dealing in unsolicited tips through like Whatsapp, Telegram, Instagram, YouTube, Facebook, SMS, calls, etc.
e) Trading / Trading in “Options” based on recommendations from unauthorised / unregistered investment advisors and influencers.

Kindly, read the Advisory Guidelines For Investors as prescribed by the Exchange with reference to their circular dated 27th August, 2021 regarding investor awareness and safeguarding client’s assets : Advisory Guidelines For Investors

Kindly, read the advisory as prescribed by the Exchange with reference to their circular dated January 14, 2022 regarding Updation of mandatory KYC fields by March 31, 2022: KYC Updation

Attention Investors: Prevent unauthorised transactions in your Demat account by updating your mobile number with your depository participant. Receive alerts on your registered mobile number for debit and other important transactions in your Demat account directly from CDSL on the same day. Prevent unauthorised transactions in your Trading account by updating your mobile numbers/email addresses with your stock brokers. Receive information on your transactions directly from the Exchange on your mobile/email at the end of the day. Issued in the interest of investors. KYC is a one-time exercise while dealing in securities markets - once KYC is done through a SEBI-registered intermediary (broker, DP, Mutual Fund, etc.), you need not undergo the same process again when you approach another intermediary. As a business, we don’t give stock tips and have not authorised anyone to trade on behalf of others. If you find anyone claiming to be part of Upstox or RKSV and offering such services, please send us an email at complaints@upstox.com and complaints.mcx@upstox.com.

No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor’s account. Stockbrokers can accept securities as margin from their clients only by way of a pledge in the depository system w.e.f. 1st September 2020.
Update your email ID and mobile number with your stockbroker/depository participant and receive an OTP directly from the depository on your registered email ID and/or mobile number to create a pledge.
Check your securities/mutual funds/bonds in the Consolidated Account Statement (CAS) issued by NSDL/CDSL every month.

Attention Investors: SEBI has established an Online Dispute Resolution Portal (ODR Portal) for resolving disputes in the Indian Securities Market. This circular streamlines the existing dispute resolution mechanism, offering online conciliation and arbitration, benefiting investors and listed companies. https://www.sebi.gov.in/legal/circulars/jul-2023/online-resolution-of-disputes-in-the-indian-securities-market_74794.html ODR portal for Investors - https://smartodr.in/login

Emcure Pharma shares list at 31% premium: Here’s how much Namita Thapar gained from share sale

Namita Thapar gains ₹168 crore after premium listing of Emcure Pharma shares

To know more about IPOs listing, schedule and upcoming IPOs, click here

Market Wrap, December 20: SENSEX, NIFTY50 nosedive again; both indices tumble around 5% this week

Mamata Machinery IPO subscribed over 34 times on Day 2, retail investors, NIIs lead; check key dates

International Gemmological Institute shares settle 7.4% lower after listing at 22% premium

KPI Green Energy, Sagility India and SPML Infra are among key stocks to hit the circuit today

Trade setup: Bearish weekly close for NIFTY?

Trade setup: Will NIFTY hold THIS crucial support zone?